Back to top
more

Aridis Pharmaceuticals (ARDS)

(Delayed Data from OTC)

$0.07 USD

0.07
24,355

0.00 (0.00%)

Updated Apr 26, 2024 02:07 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of -33.33% and 24.31%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?

Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301

by Zacks Equity Research

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug

by Zacks Equity Research

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design

by Zacks Equity Research

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.

Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More

by Zacks Equity Research

Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.

Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals

by Zacks Equity Research

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

Here's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Aridis Pharmaceuticals (ARDS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 17.78% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study

by Zacks Equity Research

DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.

Albireo (ALBO) Up on Results From Alagille Syndrome Study

by Zacks Equity Research

Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.

scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval

by Zacks Equity Research

scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.

Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study

by Zacks Equity Research

Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.

Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study

by Zacks Equity Research

Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.

Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size

by Zacks Equity Research

Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.

9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate

by Zacks Equity Research

9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.

DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold

by Zacks Equity Research

DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.

Wave Therapeutics (WVE) Up on Update From Huntington's Study

by Zacks Equity Research

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

Intellia (NTLA) Reports Positive Results for CRISPR Candidates

by Zacks Equity Research

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

by Zacks Equity Research

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?